Nebacetin does not have exclusivity to the use of ‘Neba’ or ‘Nebac’ radicals

The work of partner Eduardo Périllier in the case regarding the registration of the name of the drug “Nebacetin”, without guaranteeing protection and exclusivity for its use of the radical “Nebac”, was highlighted in the Migalhas portal this Tuesday (18 May). The article highlighted the oral arguments of the partner, who posited that the agglutination of the radicals of the active ingredients of the medicine created the prefix “Neba”, which, in addition to the main brand, formed the brand Nebacimed, leading the 4th Panel of the STJ to uphold Cimed’s appeal on the basis that the similarity between the brand names stems from the use of the prefixes of the substances that compose them.

Read the full content in Portuguese at: